Page 95 - 南京医科大学学报自然科学版
P. 95

第41卷第6期                           南京医科大学学报(自然科学版)
                  2021年6月                   Journal of Nanjing Medical University(Natural Sciences)     ·873 ·


               ·临床医学·

                浸润性乳腺癌组织 HER2 与 Ki67 联合表达与蒽环类化疗药物

                的疗效及预后相关



                赵伟志 ,赵 薇 ,杨小兵 ,赵 坤              4*
                                        3
                               3
                      1,2
                马鞍山市中心医院病理科,安徽             马鞍山    243000;绍兴市柯桥区妇幼保健院病理科,浙江               绍兴   312030;南京医科大学
                1                                       2                                            3
                附属南京医院病理科,江苏 南京             210006;淮安市肿瘤医院肿瘤科,江苏           淮安   223200
                                                  4

               [摘   要] 目的:探讨浸润性乳腺癌组织中HER2与Ki67的表达与蒽环类化疗药物疗效及临床预后的相关性。方法:数据库
                预测HER2基因在浸润性乳腺癌组织中的表达情况及与Ki67的关联性分析;利用Nanostring nCounter技术检测53例浸润性乳
                腺癌石蜡包埋组织标本中HER2的mRNA表达情况,并分析蒽环类化疗药物的疗效;收集2008—2012年浸润性乳腺癌的组织
                蜡块222例,免疫组织化学方法检测HER2与Ki67的蛋白表达情况,并结合临床病理资料、化疗疗效及预后情况进行相关性分
                析。结果:GEPIA数据库分析显示HER2 mRNA在浸润性乳腺癌组织中的表达和Ki67的表达具有相关性;Nanostring nCounter
                技术检测53例浸润性乳腺癌组织中HER2 mRNA的表达水平,阳性16/53(30.19%),阴性为37/53(69.81%),HER2阳性患者中
                3例化疗有效(18.80%),13例无效(81.20%),HER2阴性患者中19例(51.35%)有效,18例(48.65%)无效;222例浸润性乳腺癌
                临床病理资料结果显示,HER2 /Ki67 浸润性乳腺癌患者有较好的化疗疗效和预后。结论:HER2阴性浸润性乳腺癌患者中,
                                        -
                                            +
                Ki67高表达预示有较好的化疗疗效,HER2 /Ki67 的浸润性乳腺癌患者预示有较好的生存期。
                                                -
                                                     +
               [关键词] 浸润性乳腺癌;HER2;Ki67;Nanostring nCounter;化疗疗效;预后
               [中图分类号] R737.9                   [文献标志码] A                       [文章编号] 1007⁃4368(2021)06⁃873⁃07
                doi:10.7655/NYDXBNS20210613


                Expression    level   of  HER2/Ki67      is  association    with   efficacy  of   anthracycline
                chemotherapeutic drugs and clinical prognosis in invasive breast cancer

                            1,2
                                                       3
                                        3
                ZHAO Weizhi ,ZHAO Wei ,YANG Xiaobing ,ZHAO Kun    4*
                Department of Pathology,Maanshan Central Hospital,Maanshan 243000;Department of Pathology,Shaoxing
                1                                                                2
                Keqiao Women and Children Hospital,Shaoxing 312030;Department of Pathology,Nanjing First Hospital Afiliated
                                                                3
                to Nanjing Medical University,Nanjing 210006;Department of Oncology,Huai’an Tumor Hospital,Huai’an
                                                          4
                223200,China
               [Abstract] Objective:This study aims to investigate the expression level of HER2/Ki67 is association with efficacy of anthracycline
                chemotherapeutic drugs and clinical prognosis in invasive breast cancer. Methods:The expression level of HER2 and Ki67 in invasive
                breast cancer were predicted by database. The mRNA expression of HER2 in 53 cases of invasive breast cancer FFPE was detected by
                Nanostring nCounter technique,and the efficacy of anthracycline chemotherapeutic drugs was analyzed. Total 222 cases of invasive
                breast cancer tissue samples from 2008 to 2012 were collected to analyze the protein expression level of HER2 and Ki67,and the
                correlation analysis was conducted based on the clinicopathological data and the chemotherapy efficacy of the patients. Results:
                GEPIA database analysis showed that there was a correlation between the HER2 mRNA and Ki67 mRNA. The expression level of
                HER2 mRNA in 53 cases of invasive breast cancer was detected by Nanostring nCounter. The positive rate was 16/53(30.19%)and the
                negative rate was 37/53(69.81%). Among the HER2 positive patients,chemotherapy was effective in 3 cases(18.80%)and ineffective
                in 13 cases(81.20%). In the HER2 negative patients,chemotherapy was effective in 19 cases(51.35%)and ineffective in 18 cases
               (48.65%). The results of the clinicopathological data of 222 cases of invasive breast cancer showed that the invasive breast cancer

               [基金项目] 江苏省卫生健康委科研项目(Z2020005);南京医科大学科技发展基金(2017NJMUZD107)
                ∗
                通信作者(Corresponding author),E⁃mail:zhaokuntll@163.com
   90   91   92   93   94   95   96   97   98   99   100